Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Repros Therapeutics Halts Development of Proellex

By Pharmaceutical Processing | August 3, 2009

NEW YORK (AP) — Shares of Repros Therapeutics Inc. plunged Monday after the company said it is halting development of its experimental drug Proellex because of an increase in liver enzymes in patients. Meanwhile, the company said it is considering various financing alternatives to address its immediate needs. If the company can’t raise funds, it may have to further cut costs, sell assets, or possibly sell the company. Repros shares plunged $1.24, or 49 percent, to reach $1.29 in afternoon trading. The stock has traded between $1.01 and $13.94 over the last 52 weeks. The drug is being studied as a potential treatment to reduce the amount of menstrual bleeding associated with uterine fibroids, which are noncancerous growths of muscle fibers inside the uterus that can cause heavy menstrual bleeding, pelvic soreness and pain during sex. The Woodlands, Texas-based company had already suspended development of a 50-milligram dose of the drug. The latest action also cuts out the 25-milligram dose. “This decision is based on available information regarding the occurrence of clinically significant increases in liver enzymes with 50-milligrama and 25-milligram doses of Proellex, coupled with recent input from a consulting panel of liver experts,” the company said, in a statement. The company said more than 500 patients in the study received Proellex in various doses. In all, 13 had an increase in liver enzymes greater than the normal limit, and nine of those cases were confirmed after 48 hours.

Related Articles Read More >

Purdue University
Purdue University launches institute for advanced manufacturing of pharmaceuticals
Sanofi logo
Sanofi introduces its first digital accelerator 
Cambridge Pharma launches with UK plant in Cambridge Research Park
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards